Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

2014 ◽  
Vol 32 (4) ◽  
pp. 670-681 ◽  
Author(s):  
Jordi Rodon ◽  
Irene Braña ◽  
Lillian L Siu ◽  
Maja J De Jonge ◽  
Natasha Homji ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Pi3k Inhibitor ◽  
Class I ◽  
Advanced Solid Tumors

scholarly journals Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

2013 ◽  
Vol 20 (1) ◽  
pp. 233-245 ◽  
Author(s):  
Geoffrey I. Shapiro ◽  
Jordi Rodon ◽  
Cynthia Bedell ◽  
Eunice L. Kwak ◽  
Jose Baselga ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Pi3k Inhibitor ◽  
Class I ◽  
Advanced Solid Tumors ◽  
Pharmacodynamic Study

scholarly journals Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

2017 ◽  
Vol 7 (7) ◽  
pp. 704-715 ◽  
Author(s):  
Dejan Juric ◽  
Ian Krop ◽  
Ramesh K. Ramanathan ◽  
Timothy R. Wilson ◽  
Joseph A. Ware ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Pi3k Inhibitor ◽  
Advanced Solid Tumors ◽  
Dose Escalation Study

scholarly journals Phase I Dose‐Escalation Study of Pilaralisib (SAR245408, XL147), a Pan‐Class I PI3K Inhibitor, in Combination With Erlotinib in Patients With Solid Tumors

2015 ◽  
Vol 20 (3) ◽  
pp. 245-246 ◽  
Author(s):  
Jean‐Charles Soria ◽  
Patricia LoRusso ◽  
Ratislav Bahleda ◽  
Joanne Lager ◽  
Li Liu ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Pi3k Inhibitor ◽  
Class I ◽  
Dose Escalation Study

A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 3035-3035 ◽  
Author(s):  
A. Patnaik ◽  
L. J. Appleman ◽  
J. M. Mountz ◽  
R. K. Ramanathan ◽  
M. Beeram ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Phase I Study ◽  
Pi3k Inhibitor ◽  
Advanced Solid Tumors

scholarly journals Phase I dose‐escalation study of buparlisib ( BKM 120), an oral pan‐class I PI 3K inhibitor, in Japanese patients with advanced solid tumors

2014 ◽  
Vol 105 (3) ◽  
pp. 347-353 ◽  
Author(s):  
Yuichi Ando ◽  
Megumi Inada‐Inoue ◽  
Ayako Mitsuma ◽  
Takayuki Yoshino ◽  
Atsushi Ohtsu ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Japanese Patients ◽  
Class I ◽  
Advanced Solid Tumors ◽  
Dose Escalation Study

scholarly journals Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan‐Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

2018 ◽  
Vol 23 (4) ◽  
pp. 401 ◽  
Author(s):  
Gerald Edelman ◽  
Jordi Rodon ◽  
Joanne Lager ◽  
Christelle Castell ◽  
Jason Jiang ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Trial ◽  
Tablet Formulation ◽  
Pi3k Inhibitor ◽  
Class I ◽  
Advanced Solid Tumors
Sign in / Sign up

Export Citation Format

Share Document